Production (Stage)
Sensei Biotherapeutics, Inc.
SNSE
$0.295
-$0.014-4.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 66.31% | -33.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.83% | -15.34% | |||
| Operating Income | -9.83% | 15.34% | |||
| Income Before Tax | 11.66% | -7.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.66% | -7.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.66% | -7.13% | |||
| EBIT | -9.83% | 15.34% | |||
| EBITDA | -15.07% | 16.01% | |||
| EPS Basic | 11.73% | -7.04% | |||
| Normalized Basic EPS | -10.34% | 10.93% | |||
| EPS Diluted | 11.73% | -7.04% | |||
| Normalized Diluted EPS | -10.34% | 10.93% | |||
| Average Basic Shares Outstanding | 0.10% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||